SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· CIK 0001590560

QURE

uniQure N.V.
$23.46 ▲ +0.39%
Prev close $23.37
Market cap$1.7B
ConsensusStrong Buy
12-mo target$65.48 (+179.1%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (5 insiders)High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on QURE right now — valuation, ownership and activity at a glance.
Market Cap
$1.7B
Cap Size
Small Cap
Analyst Consensus
Strong Buy (90%)
Insider Activity
$0.00 buy / $16.5M sell
Insider Net $
-$16.5M
Social Sentiment
64° Warm
SEC Reports
20
Press Releases
2
Price chart 30d -47.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 10, 2026 ftd
FTD: QURE — 52,675 shares ($2.4M) failed to deliver
Settlement: 20260910, Price: $46.00, FTD Value: $2,423,050, UNIQURE N V ORD SHS (NLD)
Sep 2, 2026 SEC
uniQure announced submission of a Biologics License Application (BLA) to the FDA seeking accelerated approval of its gen
8-K — Impact 7/10
Jul 29, 2026 SEC
uniQure reported Q2 2026 results with a net loss of $1.22 per share, significantly missing the $-0.71 consensus estimate
8-K — Impact 8/10
Jul 8, 2026 SEC
Three insiders at uniQure (QURE), including the CEO and Chief Medical Officer, sold a combined $1.67M in stock within a
CLUSTER — Impact 5/10
Jul 2, 2026 Insider
Kapusta Matthew C sold 4,282 shares
CEO, Managing Director @ $45.43 ($194.5K)
Jul 2, 2026 Insider
Kapusta Matthew C sold 9,200 shares
CEO, Managing Director @ $44.43 ($408.8K)
Jul 2, 2026 Insider
Kapusta Matthew C sold 7,600 shares
CEO, Managing Director @ $45.89 ($348.8K)
Jun 24, 2026 Press
uniQure priced an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, expecting approximately
Impact 6/10
Analyst ratings buy % +5.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 90% rate it Buy or better · 20 analysts
Strong Buy 7 35% Buy 11 55% Hold 2 10% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Oct 2, 2026RBC CapitalMAINTAINOutperform 55%
Sep 30, 2026Goldman SachsMAINTAINNeutral 54%
Jul 30, 2026Wells FargoMAINTAINOverweight 54%
Jul 30, 2026Wolfe ResearchUPGRADEOutperform 52%
Jul 30, 2026BarclaysMAINTAINOverweight 54%
Jun 29, 2026HC Wainwright & Co.MAINTAINBuy 43%
Jun 25, 2026MizuhoMAINTAINOutperform 52%
Jun 18, 2026BarclaysUPGRADEOverweight 54%
Jun 18, 2026Goldman SachsMAINTAINNeutral 54%
Jun 18, 2026Leerink PartnersMAINTAINOutperform 49%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202671120090%
Aug 1, 202671120090%
Jul 1, 202661230086%
Jun 1, 202661050076%
May 1, 202661050076%
Apr 1, 202661050076%
Mar 1, 202661150077%
Feb 1, 202661130085%
Price targets
Where 11 covering analysts think QURE trades over the next 12 months.
$65.48 +179.1% upside Strong Buy
Current$23.46 Low$30.80 Median$69.54 High$91.95 11 analysts
$30.80$91.95
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment mood +7.1%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
64°
Warm
BearishNeutralBullish
3 mentions 2 bullish 0 bearish 1 neutral
Recent posts
wallstreetbets Bullish 3mo ago
$QURE Call gains
▲ 1 · 💬 0· ⚡ 0.5
options Neutral 7mo ago
$QURE -cure to yr RED portfolio?
▲ 0 · 💬 0
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 3 bullish, 3 bearish, 2 mixed, 12 neutral · avg impact 3.8/10.Plus 2 press releases.
BULLISH8-K7/10
uniQure announced submission of a Biologics License Application (BLA) to the FDA seeking accelerated
Sep 2, 2026
BULLISH8-K8/10
uniQure reported Q2 2026 results with a net loss of $1.22 per share, significantly missing the $-0.7
Jul 29, 2026
BEARISHCLUSTER5/10
Three insiders at uniQure (QURE), including the CEO and Chief Medical Officer, sold a combined $1.67
Jul 8, 2026
BEARISHCLUSTER4/10
Cluster of insider sales at uniQure following two recent $225M and $150M capital raises, with total
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 10, 2026
ftd
FTD: QURE — 52,675 shares ($2.4M) failed to deliver
Settlement: 20260910, Price: $46.00, FTD Value: $2,423,050, UNIQURE N V ORD SHS (NLD)
Jul 29, 2026
earnings
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~
Jul 29, 2026
earnings_calendar
QURE Q2 2026 Earnings Before Market Open — 2026-07-29
Jul 27, 2026
ftd
FTD: QURE — 19,009 shares ($0.7M) failed to deliver
Settlement: 20260727, Price: $38.97, FTD Value: $740,780.73, UNIQURE N V ORD SHS (NLD)
Jul 8, 2026
ftd
FTD: QURE — 31,982 shares ($1.3M) failed to deliver
Settlement: 20260708, Price: $41.41, FTD Value: $1,324,374.62, UNIQURE N V ORD SHS (NLD)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.83$-1.05–$-0.6630.8%-0.6%3↑ 0↓$0.0B10
Next Q$-0.81$-1.40–$-0.27-71.4%-1.6%3↑ 0↓$0.0B10
Current FY$-3.45$-4.21–$-3.02-17.7%-0.5%3↑ 0↓$0.0B10
Next FY$-2.69$-4.12–$-0.4721.9%-4.1%3↑ 0↓$0.1B10
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.825—
7d ago$-0.821-0.004
30d ago$-0.820-0.005
60d ago$-0.823-0.002
90d ago$-0.811-0.014
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 50 transactions. Net -$16.5M — $0.00 bought, $16.5M sold.
DateInsiderTitleTypeSharesPriceValue
Jul 2, 2026Kapusta Matthew CCEO, Managing DirectorSELL4,282$45.43$194.5K
Jul 2, 2026Kapusta Matthew CCEO, Managing DirectorSELL9,200$44.43$408.8K
Jul 2, 2026Kapusta Matthew CCEO, Managing DirectorSELL7,600$45.89$348.8K
Jul 2, 2026Kapusta Matthew CCEO, Managing DirectorEXERCISE21,082$19.39$408.8K
Jun 30, 2026Kaye JackDirectorSELL4,107$46.49$190.9K
Jun 30, 2026Abi-Saab WalidChief Medical OfficerSELL10,000$46.46$464.6K
Jun 30, 2026Abi-Saab WalidChief Medical OfficerEXERCISE10,000$5.59$55.9K
Jun 30, 2026Abi-Saab WalidChief Medical OfficerSELL20,000$46.40$928.0K
Jun 30, 2026Kaye JackDirectorEXERCISE4,107$37.00$152.0K
Jun 30, 2026Kaye JackDirectorEXERCISE17,060$20.18$344.3K
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for QURE.
Shares short
9,920,512
Settlement Sep 15, 2026
Change vs prior
+0.5%
Semi-monthly cycle
Days to cover
8.1
At avg daily volume
Of shares outstanding
≈14.3%
Estimate — not % of float
All QURE filing & press-release reports (32)